The Next Phase of Human Gene-Therapy Oversight

Abstract excerpt

The Next Phase of Human Gene-Therapy Oversight As gene therapy continues to change, so must the federal framework set up to oversee it. As new biotechnologies continue to emerge, the NIH and the FDA are proposing reductions in duplicative oversight and changes to the role of the Recombinant DNA Advisory Committee.

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Biomedical Ethics and Regulation
• Share to CAR-T cell therapy research
• Share to CRISPR and Genetic Engineering